Macromill Group

Tokyo, Jun. 24, 2020 - Macromill, Inc. (Headquarters: Minato-ku, Tokyo; Scott Ernst, Representative Executive Officer, Global CEO; hereinafter, “Macromill”) is pleased to announce that its consolidated subsidiary MACROMILL EMBRAIN CO., LTD. (hereinafter “EMBRAIN”) is expected to be listed on the KOSDAQ market and issue new stock with the scheduled date of listing on July 1, 2020 in Korea as follows. EMBRAIN has been preparing for listing on the KOSDAQ market, emerging equity market section of the Korea Exchange (KRX), as we have disclosed on March 27, 2020 as “ Notification regarding approval of Macromill’s Korean consolidated subsidiary’s initial listing on KOSDAQ market of Korea Exchange”.

1. About EMBRAIN

Macromill’s consolidated subsidiary, EMBRAIN has been leading the marketing research industry as one of the largest internet research companies in Korea. Recently, EMBRAIN has actively focused on new initiatives such as a big data service with its proprietary panels. To increase its brand awareness and recruitment of talented personnel, EMBRAIN has been preparing for the initial listing with the aim to further business growth and revenue expansion, especially digital field.

In these circumstances, EMBRAIN has come to the result that it will be expected to be listed on the KOSDAQ market, which is a stock market for emerging companies on the exchange in the Korea Exchange (KRX), and issue new stock with the scheduled date of listing on July 1, 2020.

Preparations for the listing are being conducted on the premise that EMBRAIN will continue to be Macromill’s major consolidated subsidiary, even after being listed. Macromill believes the listing and new stock issuance of EMBRAIN in Korea will contribute to the further corporate brand penetration of Embrain, strengthening the business foundation, management and financial structure as well as the future improvement of the enterprise value of EMBRAIN and our Group.

2. Outline of new stock issuance and future prospects

* Although this new stock issuance will dilute Macromill's holding share, EMBRAIN will be continued to be consolidated subsiriary of Macromill, based on the effective control standards.

The expected impact of this listing on our Group’s business results for the fiscal year ending June 2020 is immaterial. Macromill will promptly announce additional information on this initiative in the future, should they arise.

Ends